Trials / Not Yet Recruiting
Not Yet RecruitingNCT07041437
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
Efficacy and Safety Study of SHR-A2102-based Treatment in Advanced Breast Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Our study is aimed to evaluate the efficacy and safety of SHR-A2102 combined other antitumor treatments in advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A2102 | ADC |
| DRUG | Adebrelimab | PD-L1 inhibitor |
Timeline
- Start date
- 2025-06-30
- Primary completion
- 2026-09-30
- Completion
- 2027-01-31
- First posted
- 2025-06-27
- Last updated
- 2025-06-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07041437. Inclusion in this directory is not an endorsement.